This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Exon Skipping/NF-kB Program

Catabasis Pharmaceuticals, Inc.

Drug Names(s): Edasalonexent/Exon Skipping Program

Description: The Exon Skipping/NF-kB Program is a combination drug treatment of Edasalonexent and an exon skipping drug.

Deal Structure: Sarepta and Catabasis
In September 2016, Catabasis and Sarepta announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD). The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.

Partners: Sarepta Therapeutics, Inc.

Exon Skipping/NF-kB Program News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug